Results 111 to 119 of about 27,707 (119)

Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide

Journal of Pharmacy Technology, 2014
Bettina Winzeler, Esther Helen Steveling-Klein, Andreas Bircher   +2 more
exaly  

Crystal structure of the GLP-1 receptor bound to a peptide agonist

Nature, 2017
Nathan Robertson, Fiona H. Marshall, Miles Congreve   +2 more
exaly  

Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis

Cell Reports, 2020
Robert P. Doyle, Aleksandra J Wierzba, Tito Borner   +2 more
exaly  

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes

Expert Review of Clinical Pharmacology, 2017
Thomas Fremming Dejgaard, Sten Madsbad, Lauge Østergaard   +2 more
exaly  

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Regulatory Peptides, 2010
Werner Kramer, Andreas W Herling, Ulrich Werner   +2 more
exaly  

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Diabetes, Obesity and Metabolism, 2016
James L Trevaskis, Alessandra Rossi
exaly  

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis

European Stroke Journal
Sotirios Giannopoulos, Lina Palaiodimou, Georgios Tsivgoulis   +2 more
exaly  

Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials

Journal of Diabetes
Yufang Bi, Yuhong Chen, Jieli Lu
exaly  

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Lancet, The
Andreas Vegge
exaly